amantadine has been researched along with Chronic Hepatitis C in 128 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine." | 9.14 | Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. ( Adler, M; Brenard, R; D'Heygere, F; Delwaide, J; Henrion, J; Horsmans, Y; Langlet, P; Lasser, L; Laureys, A; Michielsen, P; Mulkay, JP; Nevens, F; Van Vlierberghe, H, 2009) |
| "Adding amantadine to antiviral therapy of previously untreated chronic hepatitis C patients has no beneficial effects." | 9.14 | No beneficial effects of amantadine in treatment of chronic hepatitis C patients. ( Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM, 2010) |
| "The impact of amantadine on virologic response rates of interferon-based treatment of chronic hepatitis C is controversial." | 9.13 | Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. ( Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S, 2008) |
| "Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients." | 9.12 | Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. ( Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P, 2006) |
| "There is yet no established treatment for chronic hepatitis C patients non-responder to standard interferon and ribavirin." | 9.12 | A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. ( Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M, 2006) |
| " The efficacy of induction doses of interferon-alpha-2a monotherapy or in combination with ribavirin and/or amantadine was evaluated in interferon non-responders with chronic hepatitis C." | 9.12 | Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial. ( Andrade, R; de la Mata, M; Diago, M; Granados, R; Muñoz de Rueda, P; Pérez, R; Romero, M; Ruiz-Extremera, A; Salmerón, J; Solá, R, 2007) |
| "Efficacy and safety of interferon induction therapy alone or in combination with ribavirin or ribavirin plus amantadine were evaluated in chronic hepatitis C patients who were nonresponders to primary antiviral treatment." | 9.12 | A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. ( Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G, 2007) |
| "In this randomized, prospective, placebo-controlled, multicenter trial, previously untreated patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [17] and randomized for treatment with amantadine (200 mg/day, orally, n=136) or placebo (n=131)." | 9.12 | Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. ( Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S, 2007) |
| "In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naïve patients with chronic hepatitis C virus (HCV)." | 9.11 | Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. ( Anania, FA; Black, M; Fairbanks, KD; Gelrud, LG; Lobis, IF; Maheshwari, A; Mehdi, J; Ryan, MJ; Thuluvath, PJ; Wu, LL, 2004) |
| "To evaluate the efficacy of amantadine plus interferon-alpha compared with interferon-alpha alone in naive patients with chronic hepatitis C who were randomized on the basis of the early virological response to interferon-alpha." | 9.11 | A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. ( Angelico, F; Angelico, M; Barlattani, A; Cepparulo, M; De Sanctis, G; Della Vecchia, R; Demelia, L; Di Candilo, F; Francioso, S; Gentile, S; Grieco, A; Parruti, G; Sabusco, G; Tarquini, L; Tosti, A; Zaru, S, 2004) |
| " This is the first report on the occurrence of sudden hearing loss in six cases of chronic hepatitis C in temporal relation to treatment with pegylated (PEG)-IFN alfa2a or b/ribavirin combination therapy." | 9.11 | Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. ( Denk, DM; Ferenci, P; Formann, E; Gangl, A; Jessner, W; Munda-Steindl, P; Stauber, R; Zollner, G, 2004) |
| "There is currently no accepted therapeutic regimen for patients with chronic hepatitis C who failed to respond to standard combination treatment with interferon-alpha plus ribavirin." | 9.11 | Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. ( Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P, 2004) |
| "To evaluate the efficacy of amantadine plus interferon-alpha and ribavirin in non-responder patients with chronic hepatitis C." | 9.11 | Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). ( Altintas, E; Altiparmak, E; Cicek, B; Filik, L; Kilic, M; Odemis, B; Oguz, D; Zengin, N, 2005) |
| "In an attempt to improve the efficacy of antiviral therapy for chronic hepatitis C, a three-drug combination of pegylated interferon alpha-2b, ribavirin, and amantadine has been suggested." | 9.11 | Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. ( Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM, 2005) |
| "The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C was evaluated." | 9.10 | Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. ( Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R, 2003) |
| "Thirty-seven chronic hepatitis C patients with virological relapse (VR) after previous interferon-alpha (IFN) or IFN/ribavirin (Riba) therapy, were re-treated." | 9.10 | Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. ( Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ, 2003) |
| " In this pilot study, we evaluated the efficacy of a combination of interferon, ribavirin, and amantadine in patients with chronic hepatitis C who had previously failed 6-12 months of treatment with interferon and ribavirin." | 9.10 | Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. ( Maygers, J; Pande, H; Thuluvath, PJ, 2003) |
| "The antiviral efficacy of amantadine in patients with chronic hepatitis C is controversial." | 9.10 | Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. ( Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S, 2003) |
| "Efficacy and safety of interferon-alpha (IFN-alpha)/ribavirin retreatment with or without amantadine sulphate were evaluated in non-responders with chronic hepatitis C." | 9.10 | Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. ( Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S, 2003) |
| "Despite advances in the treatment of chronic hepatitis C virus (HCV), the disease persists after treatment with interferon and ribavirin in a large percentage of patients and other therapeutic options are lacking." | 9.10 | [Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)]. ( Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C, 2003) |
| "Recent controlled trials on the efficacy of an amantadine/interferon combination in treatment-naive patients with chronic hepatitis C yielded contradictory results." | 9.10 | Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. ( Borovicka, J; Cathomas, G; Dufour, JF; Gonvers, JJ; Helbling, B; Reichen, J; Renner, EL; Sagmeister, M; Stamenic, I; Steuerwald, M; Viani, F, 2002) |
| "We report two patients with chronic hepatitis C, both nonresponders to a previous course of interferon (IFN), who developed or suffered an exacerbation of sarcoidosis while under treatment with IFN-alpha2a, ribavirin and amantadine." | 9.10 | Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. ( Lombraña, JL; Pérez-Alvarez, R; Pérez-López, R; Rodrigo, L; Rodríguez, M, 2002) |
| "Although the antiviral effects of amantadine sulphate (1-aminoadamantan sulphate) have not been characterized for the hepatitis C virus (HCV), previous pilot studies have suggested promising results in patients with chronic hepatitis C." | 9.09 | Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. ( Berg, T; Hartmann, S; Hopf, U; Naumann, U; Raedle, J; Teuber, G; Zeuzem, S, 2000) |
| "Interferon (IFN) alpha in combination with ribavirin (RIB) is standard therapy for patients with chronic hepatitis C virus (HCV) infection." | 9.09 | HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. ( Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R, 2000) |
| "We conducted a pilot study to determine the efficacy and the safety of amantadine as initial therapy in patients with chronic hepatitis C." | 9.09 | Amantadine for chronic hepatitis C: pilot study in 14 patients. ( Andant, C; Deybach, JC; Jouet, P; Lamoril, J; Soulé, JC, 2000) |
| "The aim of this study was to compare, in an open-label study, the efficacy and safety of a combination of interferon (IFN) and amantadine (AMA) with that of IFN alone in previously untreated patients with chronic hepatitis C." | 9.09 | A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. ( Andriulli, A; Annese, M; Bacca, D; Bisceglia, M; Carretta, V; Dell'Erba, G; Giangaspero, A; Leandro, G; Mangia, A; Minerva, N; Santoro, R; Ventrella, F; Villani, MR, 2001) |
| "Multi-centre trial including 180 chronic hepatitis C patients without cirrhosis, randomly enrolled to receive interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months (group A, 90 patients), or the same schedule plus amantadine 200 mg/day (group B, 90 patients)." | 9.09 | Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. ( Andreoni, M; Biglino, A; Bonardi, R; Brunello, F; Calleri, G; Cariti, G; Chieppa, F; Cusumano, S; Della Monica, P; Delmastro, B; Laudi, C; Manca, A; Pera, A; Rizzetto, M; Sidoli, L; Tabone, M, 2001) |
| "Amantadine monotherapy in chronic hepatitis C patients may be effective in terms of reducing biochemical markers, but this effect was not associated with loss of viremia." | 9.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "To investigate the effects and tolerance of amantadine in chronic hepatitis C patients." | 9.08 | Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. ( Bonino, F; Ercole, E; Pera, A; Sallio Bruno, F; Tabone, M; Zaffino, C, 1998) |
| "To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C." | 8.90 | Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. ( Awad, T; Brok, J; Gluud, C; Gluud, LL; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K, 2014) |
| "In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results." | 8.82 | Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. ( Andriulli, A; Berg, T; Caronia, S; Cino, N; Di Marco, V; Foster, GR; Helbling, B; Leandro, G; Mangia, A; Renner, EL; Sidoli, L; Tabone, M; Zeuzem, S, 2004) |
| " The weight reduction--after two ineffective antiviral treatments--helped the biochemical and virological response to combined peginterferon-alpha-2a and ribavirin treatment." | 7.74 | [Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. ( Fehér, J; Hagymási, K, 2008) |
| "Amantadine reduces liver transaminase levels in some patients with chronic hepatitis C at doses of 200 mg daily and may improve the sustained virological response (SVR) when given with interferon and ribavirin." | 7.72 | Amantadine therapy for chronic hepatitis C: a dose escalation study. ( Bingaman, S; Mauger, DT; Riley, TR; Smith, JP, 2004) |
| "Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders." | 7.71 | Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. ( Berg, T; Hopf, U; Naumann, U; Wiedenmann, B, 2001) |
| "We aimed to test the efficacy of amantadine in chronic hepatitis C (CHC) patients infected with genotype b." | 7.70 | Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb. ( Akdogan, M; Badur, S; Basaran, G; Mert, A; Ozbay, G; Senturk, H; Tabak, F; Turkoglu, S, 2000) |
| "Amantadine has a potential anti-inflammatory activity that can be a safe alternative for NR-CHC subjects to combination therapy." | 6.77 | Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study. ( Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M, 2012) |
| "Predictors of liver fibrosis using APRI and Forns indices were also evaluated." | 6.75 | A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. ( Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H, 2010) |
| "Standard treatment of chronic hepatitis C virus (HCV) infection based on interferon is not an option in renal transplant recipients due to the high risk of acute allograft rejection." | 6.73 | Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. ( Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP, 2007) |
| "5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A) or (ii) IFN alone at the same dosage and duration (group B)." | 6.70 | Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. ( Ascione, T; Budillon, G; Cimino, L; Gaeta, GB; Pasquazzi, C; Piccinino, F; Stanzione, M; Stornaiuolo, G; Taliani, G, 2001) |
| "Amantadine has been reported to have the potential to produce viral suppression in patients with hepatitis C." | 6.69 | Treatment of chronic hepatitis C with amantadine. ( Goff, JS; Johnson, J; Reveille, RM, 2000) |
| " Further investigations are needed to define optimal dosing and formulation of amantadine, and its appropriate role in management of CHC infection." | 6.43 | Amantadine in treatment of chronic hepatitis C virus infection? ( Cheung, RC; Lim, JK; Siegel, R; Wooten, D, 2005) |
| " A variety of drugs have been investigated alone or in combination with alpha interferons." | 6.40 | The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. ( Perrillo, RP; Younossi, ZM, 1999) |
| "Amantadine treatment was not associated with CD81 expression." | 5.36 | Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. ( Hartmann, RW; Herrmann, E; Hofmann, WP; Kronenberger, B; Ochs, D; Piiper, A; von Wagner, M; Welker, MW; Zeuzem, S; Zimmer, V, 2010) |
| "In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-alpha2a (180 microg once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine." | 5.14 | Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. ( Adler, M; Brenard, R; D'Heygere, F; Delwaide, J; Henrion, J; Horsmans, Y; Langlet, P; Lasser, L; Laureys, A; Michielsen, P; Mulkay, JP; Nevens, F; Van Vlierberghe, H, 2009) |
| "Adding amantadine to antiviral therapy of previously untreated chronic hepatitis C patients has no beneficial effects." | 5.14 | No beneficial effects of amantadine in treatment of chronic hepatitis C patients. ( Boland, GJ; de Vries, RA; Drenth, JP; Houben, P; Koek, GH; Lieverse, RJ; Schipper, ME; Siersema, PD; van der Schaar, PJ; van der Sluys Veer, A; van Erpecum, KJ; van Hoek, B; van Ooteghem, NA; van Soest, H; Vrolijk, JM, 2010) |
| "The impact of amantadine on virologic response rates of interferon-based treatment of chronic hepatitis C is controversial." | 5.13 | Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. ( Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S, 2008) |
| "Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients." | 5.12 | Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. ( Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P, 2006) |
| "There is yet no established treatment for chronic hepatitis C patients non-responder to standard interferon and ribavirin." | 5.12 | A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. ( Andreoni, M; Anselmo, M; Basso, M; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Cusumano, S; Gallo, M; Garbagnoli, P; Giordanino, C; Grasso, A; Manca, A; Marenco, G; Percario, G; Picciotto, A; Rizzetto, M; Rizzi, R; Saracco, G; Sartori, M; Smedile, A; Tabone, M, 2006) |
| " The efficacy of induction doses of interferon-alpha-2a monotherapy or in combination with ribavirin and/or amantadine was evaluated in interferon non-responders with chronic hepatitis C." | 5.12 | Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial. ( Andrade, R; de la Mata, M; Diago, M; Granados, R; Muñoz de Rueda, P; Pérez, R; Romero, M; Ruiz-Extremera, A; Salmerón, J; Solá, R, 2007) |
| "Efficacy and safety of interferon induction therapy alone or in combination with ribavirin or ribavirin plus amantadine were evaluated in chronic hepatitis C patients who were nonresponders to primary antiviral treatment." | 5.12 | A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. ( Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G, 2007) |
| "In this randomized, prospective, placebo-controlled, multicenter trial, previously untreated patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [17] and randomized for treatment with amantadine (200 mg/day, orally, n=136) or placebo (n=131)." | 5.12 | Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. ( Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S, 2007) |
| "In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naïve patients with chronic hepatitis C virus (HCV)." | 5.11 | Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. ( Anania, FA; Black, M; Fairbanks, KD; Gelrud, LG; Lobis, IF; Maheshwari, A; Mehdi, J; Ryan, MJ; Thuluvath, PJ; Wu, LL, 2004) |
| "To evaluate the efficacy of amantadine plus interferon-alpha compared with interferon-alpha alone in naive patients with chronic hepatitis C who were randomized on the basis of the early virological response to interferon-alpha." | 5.11 | A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. ( Angelico, F; Angelico, M; Barlattani, A; Cepparulo, M; De Sanctis, G; Della Vecchia, R; Demelia, L; Di Candilo, F; Francioso, S; Gentile, S; Grieco, A; Parruti, G; Sabusco, G; Tarquini, L; Tosti, A; Zaru, S, 2004) |
| "After 6 months of amantadine therapy (200 mg per day), there were no decrease in HCV viremia (5." | 5.11 | Amantadine therapy in renal transplant patients with hepatitis C virus infection. ( Durand, D; Izopet, J; Kamar, N; Ribes, D; Rostaing, L; Sandres-Saune, K, 2004) |
| " This is the first report on the occurrence of sudden hearing loss in six cases of chronic hepatitis C in temporal relation to treatment with pegylated (PEG)-IFN alfa2a or b/ribavirin combination therapy." | 5.11 | Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. ( Denk, DM; Ferenci, P; Formann, E; Gangl, A; Jessner, W; Munda-Steindl, P; Stauber, R; Zollner, G, 2004) |
| "Interferon and ribavirin combination therapy for chronic hepatitis C induces a low response rate in human immunodeficiency virus (HIV) infected patients." | 5.11 | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. ( Artioli, S; Carosi, G; Maggiolo, F; Mignani, E; Paraninfo, G; Pastore, G; Puoti, M; Quinzan, GP; Raise, E; Ravasio, L; Resta, F; Rollo, A; Santantonio, T; Suter, F; Verucchi, G; Zaltron, S; Zanini, B, 2004) |
| "There is currently no accepted therapeutic regimen for patients with chronic hepatitis C who failed to respond to standard combination treatment with interferon-alpha plus ribavirin." | 5.11 | Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. ( Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P, 2004) |
| "To evaluate the efficacy of amantadine plus interferon-alpha and ribavirin in non-responder patients with chronic hepatitis C." | 5.11 | Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). ( Altintas, E; Altiparmak, E; Cicek, B; Filik, L; Kilic, M; Odemis, B; Oguz, D; Zengin, N, 2005) |
| "In an attempt to improve the efficacy of antiviral therapy for chronic hepatitis C, a three-drug combination of pegylated interferon alpha-2b, ribavirin, and amantadine has been suggested." | 5.11 | Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. ( Barnes, DS; Bringman, D; Carey, WD; Farmer, D; Ferguson, R; Gramlich, T; Levinthal, G; Martin, LM; McCullough, AC; Mullen, KD; O'Shea, R; Ong, JP; Post, A; Tavill, AS; Younossi, ZM, 2005) |
| "The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C was evaluated." | 5.10 | Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. ( Adinolfi, LE; Ruggiero, G; Tonziello, A; Utili, R, 2003) |
| "Thirty-seven chronic hepatitis C patients with virological relapse (VR) after previous interferon-alpha (IFN) or IFN/ribavirin (Riba) therapy, were re-treated." | 5.10 | Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. ( Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ, 2003) |
| " In this pilot study, we evaluated the efficacy of a combination of interferon, ribavirin, and amantadine in patients with chronic hepatitis C who had previously failed 6-12 months of treatment with interferon and ribavirin." | 5.10 | Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. ( Maygers, J; Pande, H; Thuluvath, PJ, 2003) |
| "The antiviral efficacy of amantadine in patients with chronic hepatitis C is controversial." | 5.10 | Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. ( Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Herrmann, E; Hinrichsen, H; Hopf, U; Kronenberger, B; Nasser, S; Pape, GR; Spengler, U; Wursthorn, K; Zeuzem, S, 2003) |
| "Efficacy and safety of interferon-alpha (IFN-alpha)/ribavirin retreatment with or without amantadine sulphate were evaluated in non-responders with chronic hepatitis C." | 5.10 | Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. ( Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S, 2003) |
| "Despite advances in the treatment of chronic hepatitis C virus (HCV), the disease persists after treatment with interferon and ribavirin in a large percentage of patients and other therapeutic options are lacking." | 5.10 | [Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)]. ( Calleja, JL; Castillo, P; Erdozain, JC; Escartín, P; Olveira, A; Segura, JM; Serrano, C, 2003) |
| "Recent controlled trials on the efficacy of an amantadine/interferon combination in treatment-naive patients with chronic hepatitis C yielded contradictory results." | 5.10 | Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. ( Borovicka, J; Cathomas, G; Dufour, JF; Gonvers, JJ; Helbling, B; Reichen, J; Renner, EL; Sagmeister, M; Stamenic, I; Steuerwald, M; Viani, F, 2002) |
| "We report two patients with chronic hepatitis C, both nonresponders to a previous course of interferon (IFN), who developed or suffered an exacerbation of sarcoidosis while under treatment with IFN-alpha2a, ribavirin and amantadine." | 5.10 | Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. ( Lombraña, JL; Pérez-Alvarez, R; Pérez-López, R; Rodrigo, L; Rodríguez, M, 2002) |
| "Twenty consecutive adult patients with chronic hepatitis C who had failed to respond to a 6-month course of interferon alpha were randomly assigned to receive a combination of interferon alpha + oral ribavirin (double therapy), or the same combination + oral amantadine (triple therapy), for 6 months." | 5.09 | Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. ( Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C, 1999) |
| "The aim of the study was to evaluate the efficacy of triple antiviral therapy with interferon, ribavirin, and amantadine in comparison with interferon and ribavirin combination treatment in patients with interferon-nonresponsive chronic hepatitis C." | 5.09 | Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. ( Bolondi, L; Brillanti, S; Foli, M; Levantesi, F; Masi, L, 2000) |
| "Although the antiviral effects of amantadine sulphate (1-aminoadamantan sulphate) have not been characterized for the hepatitis C virus (HCV), previous pilot studies have suggested promising results in patients with chronic hepatitis C." | 5.09 | Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. ( Berg, T; Hartmann, S; Hopf, U; Naumann, U; Raedle, J; Teuber, G; Zeuzem, S, 2000) |
| "Interferon (IFN) alpha in combination with ribavirin (RIB) is standard therapy for patients with chronic hepatitis C virus (HCV) infection." | 5.09 | HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. ( Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R, 2000) |
| "We conducted a pilot study to determine the efficacy and the safety of amantadine as initial therapy in patients with chronic hepatitis C." | 5.09 | Amantadine for chronic hepatitis C: pilot study in 14 patients. ( Andant, C; Deybach, JC; Jouet, P; Lamoril, J; Soulé, JC, 2000) |
| "The aim of this study was to compare, in an open-label study, the efficacy and safety of a combination of interferon (IFN) and amantadine (AMA) with that of IFN alone in previously untreated patients with chronic hepatitis C." | 5.09 | A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. ( Andriulli, A; Annese, M; Bacca, D; Bisceglia, M; Carretta, V; Dell'Erba, G; Giangaspero, A; Leandro, G; Mangia, A; Minerva, N; Santoro, R; Ventrella, F; Villani, MR, 2001) |
| "Multi-centre trial including 180 chronic hepatitis C patients without cirrhosis, randomly enrolled to receive interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months (group A, 90 patients), or the same schedule plus amantadine 200 mg/day (group B, 90 patients)." | 5.09 | Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. ( Andreoni, M; Biglino, A; Bonardi, R; Brunello, F; Calleri, G; Cariti, G; Chieppa, F; Cusumano, S; Della Monica, P; Delmastro, B; Laudi, C; Manca, A; Pera, A; Rizzetto, M; Sidoli, L; Tabone, M, 2001) |
| "Amantadine monotherapy in chronic hepatitis C patients may be effective in terms of reducing biochemical markers, but this effect was not associated with loss of viremia." | 5.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "To investigate the effects and tolerance of amantadine in chronic hepatitis C patients." | 5.08 | Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. ( Bonino, F; Ercole, E; Pera, A; Sallio Bruno, F; Tabone, M; Zaffino, C, 1998) |
| "To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C." | 4.90 | Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. ( Awad, T; Brok, J; Gluud, C; Gluud, LL; Hauser, G; Mabrouk, M; Štimac, D; Thorlund, K, 2014) |
| "This systematic review has identified evidence of very low quality for the key outcomes of all-cause mortality or liver-related morbidity and adverse events in people with chronic hepatitis C when treated with amantadine compared with ribavirin, mycophenolate, interferon-alpha, or interferon-gamma." | 4.90 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. ( Broekman, M; Drenth, JP; Gluud, C; Lamers, MH, 2014) |
| "Peginterferon plus ribavirin may be considered a treatment for patients with chronic hepatitis C and stable HIV who have not received treatment for hepatitis C as the intervention may clear the blood of HCV RNA." | 4.86 | Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. ( Awad, T; Gluud, LL; Iorio, A; Marchesini, E, 2010) |
| "Acute and chronic hepatitis C virus (HCV) infection remains a serious health problem worldwide, however, there has been advancement in the treatment of HCV infection due to standard treatment using pegylated interferon and ribavirin." | 4.84 | Treatment of hepatitis C virus infection. ( Encke, J; Stremmel, W; Weigand, K, 2007) |
| "In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results." | 4.82 | Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. ( Andriulli, A; Berg, T; Caronia, S; Cino, N; Di Marco, V; Foster, GR; Helbling, B; Leandro, G; Mangia, A; Renner, EL; Sidoli, L; Tabone, M; Zeuzem, S, 2004) |
| "A significant proportion of chronic hepatitis C patients fails to achieve sustained virologic response even after treatment with the current, more potent, combination of pegylated interferon-alpha (IFNa) plus ribavirin." | 4.82 | Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. ( Cholongitas, E; Papatheodoridis, GV, 2004) |
| "The combination of peginterferon and ribavirin is the most effective therapy for patients with chronic hepatitis C virus (HCV) infection." | 4.82 | Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. ( Sethi, A; Shiffman, ML, 2005) |
| " At present the recommended treatment for patients with chronic hepatitis C is a combination of pegylated interferon and ribavirin." | 4.82 | [Current treatment of hepatitis C virus infection]. ( Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J, 2005) |
| " The weight reduction--after two ineffective antiviral treatments--helped the biochemical and virological response to combined peginterferon-alpha-2a and ribavirin treatment." | 3.74 | [Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. ( Fehér, J; Hagymási, K, 2008) |
| "In this report, we describe five cases of chronic hepatitis C that have been treated with the combination of amantadine and ribavirin for an average of 44 months, emphasizing one case where the patient showed improvement in liver biopsy after treatment, worsening on removal, then a repeated improvement with re-initiation." | 3.74 | Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series. ( Riley, TR; Taheri, MR, 2007) |
| " We report on a patient with chronic hepatitis C, deficit of G6P-DH, type II MC, who developed a cryoglobulinemic vasculitis with purpura, renal impairment and arterial hypertension, during treatment with PEG-interferon a-2b plus amantadine." | 3.74 | Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. ( Aguilar Marucco, D; Cariti, G; De Blasi, T; De Rosa, FG; Di Perri, G; Maiello, A, 2008) |
| "The study population consisted of 53 HBsAg-negative patients with chronic hepatitis C treated with IFN/ribavirin or IFN/ribavirin/amantadine." | 3.73 | Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. ( Chemin, I; Guillaud, O; Khattab, E; Mrani, S; Trepo, C; Vieux, C; Vuillermoz, I; Zoulim, F, 2005) |
| "Antiviral treatment with pegylated interferon (PEG-IFN) and ribavirin for chronic hepatitis C improved the rates of viral clearance to 56%." | 3.73 | Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. ( Basso, M; Delfino, A; Pelli, N; Picciotto, A; Torre, F, 2006) |
| "Amantadine reduces liver transaminase levels in some patients with chronic hepatitis C at doses of 200 mg daily and may improve the sustained virological response (SVR) when given with interferon and ribavirin." | 3.72 | Amantadine therapy for chronic hepatitis C: a dose escalation study. ( Bingaman, S; Mauger, DT; Riley, TR; Smith, JP, 2004) |
| "Ten patients with chronic hepatitis C undergoing antiviral combination therapy with interferon-alpha, ribavirin, and amantadine were studied." | 3.71 | Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C. ( Balija, M; Bingulac-Popovic, J; Drazic, V; Grahovac, B; Grgicevic, D; Hrstic, I; Ostojic, R; Vucelic, B, 2001) |
| "Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders." | 3.71 | Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. ( Berg, T; Hopf, U; Naumann, U; Wiedenmann, B, 2001) |
| "The effects of amantadine (1-5 microM) and interferon alpha (IFNalpha)-2a alone (1000 IU/ml) and combined, have been studied in cultured peripheral blood mononuclear cells (PBMC) from 15 chronic hepatitis C patients and ten healthy donors." | 3.70 | In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. ( Carreño, V; Fernández, M; Martín, J; Navas, S; Pardo, M; Quiroga, JA; Rico, M; Zahm, F, 1999) |
| "We aimed to test the efficacy of amantadine in chronic hepatitis C (CHC) patients infected with genotype b." | 3.70 | Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb. ( Akdogan, M; Badur, S; Basaran, G; Mert, A; Ozbay, G; Senturk, H; Tabak, F; Turkoglu, S, 2000) |
| "Amantadine has a potential anti-inflammatory activity that can be a safe alternative for NR-CHC subjects to combination therapy." | 2.77 | Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study. ( Beyler, AR; Coban, S; Dökmeci, A; Ekiz, F; Erdem, H; Köklü, S; Ormeci, N; Ozkan, H; Palabıyıkoğlu, M, 2012) |
| "Predictors of liver fibrosis using APRI and Forns indices were also evaluated." | 2.75 | A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. ( Chirino, RA; Chung, RT; Corey, KE; Dehesa-Violante, M; Gorospe, EC; Juarez, JA; Méndez-Navarro, J; Morán, S; Zheng, H, 2010) |
| "Standard treatment of chronic hepatitis C virus (HCV) infection based on interferon is not an option in renal transplant recipients due to the high risk of acute allograft rejection." | 2.73 | Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. ( Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP, 2007) |
| "Type 1 diabetes is a rare but serious complication of interferon therapy." | 2.71 | [Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha]. ( Peters, T; Rasenack, J; Reincke, M; Schories, M, 2004) |
| "5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A) or (ii) IFN alone at the same dosage and duration (group B)." | 2.70 | Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. ( Ascione, T; Budillon, G; Cimino, L; Gaeta, GB; Pasquazzi, C; Piccinino, F; Stanzione, M; Stornaiuolo, G; Taliani, G, 2001) |
| "Amantadine has been reported to have the potential to produce viral suppression in patients with hepatitis C." | 2.69 | Treatment of chronic hepatitis C with amantadine. ( Goff, JS; Johnson, J; Reveille, RM, 2000) |
| " Further investigations are needed to define optimal dosing and formulation of amantadine, and its appropriate role in management of CHC infection." | 2.43 | Amantadine in treatment of chronic hepatitis C virus infection? ( Cheung, RC; Lim, JK; Siegel, R; Wooten, D, 2005) |
| " Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches." | 2.43 | Treating viral hepatitis C: efficacy, side effects, and complications. ( Cornberg, M; Manns, MP; Wedemeyer, H, 2006) |
| "There is room for improvement in the treatment of chronic hepatitis C with standard interferon (IFN) alfa." | 2.42 | Role of amantadine and other adjuvant therapies in the treatment of hepatitis C. ( Brillanti, S, 2004) |
| "Despite improvements in the treatment of chronic hepatitis C virus (HCV) infection, nearly half of all patients do not respond to initial therapy." | 2.42 | Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. ( Shiffman, ML, 2004) |
| " A variety of drugs have been investigated alone or in combination with alpha interferons." | 2.40 | The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. ( Perrillo, RP; Younossi, ZM, 1999) |
| "Amantadine treatment was not associated with CD81 expression." | 1.36 | Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. ( Hartmann, RW; Herrmann, E; Hofmann, WP; Kronenberger, B; Ochs, D; Piiper, A; von Wagner, M; Welker, MW; Zeuzem, S; Zimmer, V, 2010) |
| "The objective of treatment for chronic hepatitis C is to prevent in the long term the complications and death that this disease may cause." | 1.36 | Chronic hepatitis C treatment in näive patients. ( Daruich, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (9.38) | 18.2507 |
| 2000's | 103 (80.47) | 29.6817 |
| 2010's | 13 (10.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vermehren, A | 1 |
| Welsch, C | 2 |
| Elsler, U | 1 |
| Vermehren, J | 1 |
| Herrmann, E | 7 |
| Sarrazin, C | 2 |
| von Wagner, M | 4 |
| Susser, S | 1 |
| Hofmann, WP | 4 |
| Kronenberger, B | 5 |
| Zeuzem, S | 12 |
| Mihm, U | 2 |
| Khokhar, N | 2 |
| Qureshi, MO | 1 |
| Niazi, TK | 1 |
| Hauser, G | 1 |
| Awad, T | 2 |
| Brok, J | 1 |
| Thorlund, K | 1 |
| Štimac, D | 1 |
| Mabrouk, M | 1 |
| Gluud, C | 3 |
| Gluud, LL | 2 |
| Lamers, MH | 2 |
| Broekman, M | 2 |
| Drenth, JP | 4 |
| Angelico, M | 2 |
| Koehler-Horst, B | 1 |
| Piccolo, P | 2 |
| Angelico, F | 2 |
| Gentile, S | 2 |
| Francioso, S | 2 |
| Tarquini, P | 1 |
| Vecchia, RD | 1 |
| Ponti, L | 1 |
| Pilleri, G | 1 |
| Barlattani, A | 2 |
| Grieco, A | 2 |
| Soccorsi, F | 1 |
| Guarascio, P | 1 |
| Demelia, L | 2 |
| Sorbello, O | 1 |
| Rossi, Z | 1 |
| Forlini, G | 1 |
| Zaru, S | 2 |
| Bandiera, F | 1 |
| Griffin, S | 1 |
| Trowbridge, R | 1 |
| Thommes, P | 1 |
| Parry, N | 1 |
| Rowlands, D | 1 |
| Harris, M | 1 |
| Bright, H | 1 |
| Teuber, G | 6 |
| Berg, T | 9 |
| Goeser, T | 3 |
| Spengler, U | 3 |
| Hinrichsen, H | 3 |
| Weidenbach, H | 2 |
| Gerken, G | 1 |
| Manns, M | 1 |
| Buggisch, P | 3 |
| Hagymási, K | 1 |
| Fehér, J | 1 |
| Chrissafidou, A | 1 |
| Musch, E | 2 |
| Langlet, P | 1 |
| D'Heygere, F | 1 |
| Henrion, J | 2 |
| Adler, M | 1 |
| Delwaide, J | 1 |
| Van Vlierberghe, H | 1 |
| Mulkay, JP | 1 |
| Lasser, L | 1 |
| Brenard, R | 1 |
| Horsmans, Y | 1 |
| Michielsen, P | 1 |
| Laureys, A | 1 |
| Nevens, F | 1 |
| Kok, KF | 1 |
| van Soest, H | 2 |
| van Herwaarden, AE | 1 |
| van Oijen, MG | 1 |
| Boland, GJ | 2 |
| Halangk, J | 1 |
| de Vries, RA | 2 |
| Méndez-Navarro, J | 1 |
| Chirino, RA | 1 |
| Corey, KE | 1 |
| Gorospe, EC | 1 |
| Zheng, H | 1 |
| Morán, S | 1 |
| Juarez, JA | 1 |
| Chung, RT | 1 |
| Dehesa-Violante, M | 1 |
| van der Schaar, PJ | 1 |
| Koek, GH | 1 |
| van Ooteghem, NA | 1 |
| van Hoek, B | 1 |
| Vrolijk, JM | 1 |
| Lieverse, RJ | 1 |
| Houben, P | 1 |
| van der Sluys Veer, A | 1 |
| Siersema, PD | 1 |
| Schipper, ME | 1 |
| van Erpecum, KJ | 1 |
| Iorio, A | 1 |
| Marchesini, E | 1 |
| Welker, MW | 1 |
| Ochs, D | 1 |
| Zimmer, V | 1 |
| Piiper, A | 1 |
| Hartmann, RW | 1 |
| Daruich, J | 1 |
| Palabıyıkoğlu, M | 1 |
| Ormeci, N | 1 |
| Ekiz, F | 1 |
| Beyler, AR | 1 |
| Erdem, H | 1 |
| Dökmeci, A | 1 |
| Ozkan, H | 1 |
| Köklü, S | 1 |
| Coban, S | 1 |
| Ahmad, J | 1 |
| Vargas, H | 1 |
| Balan, V | 1 |
| Rakela, J | 1 |
| Shakil, AO | 1 |
| Gervais, A | 1 |
| Zoulim, F | 2 |
| Leroy, V | 1 |
| Hilleret, MN | 1 |
| Asselah, T | 1 |
| Ullerich, H | 1 |
| Avenhaus, W | 1 |
| Poremba, C | 1 |
| Domschke, W | 1 |
| Menzel, J | 1 |
| Dantzler, TE | 1 |
| Lawitz, EJ | 1 |
| Lake-Bakaar, G | 1 |
| Ruffini, L | 1 |
| Kuzmic, P | 1 |
| Adinolfi, LE | 1 |
| Utili, R | 1 |
| Tonziello, A | 1 |
| Ruggiero, G | 1 |
| Weegink, CJ | 1 |
| Sentjens, RE | 1 |
| Beld, MG | 1 |
| Dijkgraaf, MG | 1 |
| Reesink, HW | 1 |
| Thuluvath, PJ | 2 |
| Pande, H | 1 |
| Maygers, J | 1 |
| Gerlach, T | 2 |
| Nasser, S | 2 |
| Wursthorn, K | 2 |
| Pape, GR | 2 |
| Hopf, U | 5 |
| Pascu, M | 1 |
| Lafrenz, M | 1 |
| Pausch, J | 1 |
| Kullmann, F | 1 |
| Ramadori, G | 1 |
| Arnold, R | 1 |
| Junge, U | 1 |
| Wiedmann, KH | 1 |
| Zankel, M | 1 |
| Rodés, J | 1 |
| Olveira, A | 1 |
| Serrano, C | 1 |
| Erdozain, JC | 1 |
| Calleja, JL | 1 |
| Castillo, P | 1 |
| Segura, JM | 1 |
| Escartín, P | 1 |
| Lunel, F | 2 |
| Veillon, P | 1 |
| Fouchard-Hubert, I | 1 |
| Loustaud-Ratti, V | 1 |
| Abergel, A | 1 |
| Silvain, C | 1 |
| Rifflet, H | 1 |
| Blanchi, A | 1 |
| Causse, X | 1 |
| Bacq, Y | 1 |
| Payan, C | 1 |
| Brillanti, S | 4 |
| Levantesi, F | 2 |
| Nigro, G | 1 |
| Vicari, S | 1 |
| Roda, E | 1 |
| Maheshwari, A | 1 |
| Mehdi, J | 1 |
| Fairbanks, KD | 1 |
| Wu, LL | 1 |
| Gelrud, LG | 1 |
| Ryan, MJ | 1 |
| Anania, FA | 1 |
| Lobis, IF | 1 |
| Black, M | 1 |
| Engler, S | 1 |
| Flechtenmacher, C | 1 |
| Wiedemann, KH | 1 |
| Gugler, R | 1 |
| Stremmel, W | 2 |
| Kallinowski, B | 1 |
| Cepparulo, M | 1 |
| Di Candilo, F | 1 |
| Della Vecchia, R | 1 |
| De Sanctis, G | 1 |
| Parruti, G | 1 |
| Sabusco, G | 1 |
| Tarquini, L | 1 |
| Tosti, A | 1 |
| Kamar, N | 1 |
| Rostaing, L | 1 |
| Sandres-Saune, K | 1 |
| Ribes, D | 1 |
| Durand, D | 1 |
| Izopet, J | 1 |
| Mangia, A | 3 |
| Leandro, G | 2 |
| Helbling, B | 2 |
| Renner, EL | 3 |
| Tabone, M | 4 |
| Sidoli, L | 2 |
| Caronia, S | 2 |
| Foster, GR | 3 |
| Di Marco, V | 1 |
| Cino, N | 1 |
| Andriulli, A | 3 |
| Formann, E | 2 |
| Stauber, R | 2 |
| Denk, DM | 1 |
| Jessner, W | 2 |
| Zollner, G | 1 |
| Munda-Steindl, P | 1 |
| Gangl, A | 2 |
| Ferenci, P | 2 |
| Schories, M | 1 |
| Peters, T | 1 |
| Rasenack, J | 1 |
| Reincke, M | 1 |
| Torre, F | 4 |
| Rossol, S | 1 |
| Pelli, N | 2 |
| Basso, M | 3 |
| Delfino, A | 2 |
| Picciotto, A | 5 |
| Smith, JP | 2 |
| Riley, TR | 3 |
| Bingaman, S | 1 |
| Mauger, DT | 1 |
| Cottoni, F | 1 |
| Bolognini, S | 1 |
| Deplano, A | 1 |
| Garrucciu, G | 1 |
| Manzoni, NE | 1 |
| Careddu, GF | 1 |
| Montesu, MA | 1 |
| Tocco, A | 1 |
| Lissia, A | 1 |
| Solinas, A | 1 |
| Devenyi, A | 1 |
| Bingaman, SI | 1 |
| Kunselman, A | 1 |
| Papatheodoridis, GV | 1 |
| Cholongitas, E | 1 |
| Puoti, M | 1 |
| Zanini, B | 1 |
| Quinzan, GP | 1 |
| Ravasio, L | 1 |
| Paraninfo, G | 1 |
| Santantonio, T | 1 |
| Rollo, A | 1 |
| Artioli, S | 1 |
| Maggiolo, F | 1 |
| Zaltron, S | 1 |
| Raise, E | 1 |
| Mignani, E | 1 |
| Resta, F | 1 |
| Verucchi, G | 2 |
| Pastore, G | 1 |
| Suter, F | 1 |
| Carosi, G | 1 |
| Deltenre, P | 1 |
| Canva, V | 1 |
| Dharancy, S | 1 |
| Texier, F | 1 |
| Louvet, A | 1 |
| De Maeght, S | 1 |
| Paris, JC | 1 |
| Mathurin, P | 1 |
| Tanaka, K | 1 |
| Hasan, F | 1 |
| Al-Khaldi, J | 1 |
| Asker, H | 1 |
| Al-Ajmi, M | 1 |
| Owayed, S | 1 |
| Varghese, R | 1 |
| Siddique, I | 1 |
| Al-Nakib, B | 1 |
| Shiffman, ML | 3 |
| Vogel, W | 1 |
| Stauber, RE | 1 |
| Hofer, H | 1 |
| Hackl, F | 2 |
| Schütze, K | 1 |
| Datz, C | 2 |
| Hegenbarth, K | 1 |
| Steindl-Munda, P | 2 |
| Peter, F | 1 |
| Davis, GL | 1 |
| Oguz, D | 1 |
| Cicek, B | 1 |
| Filik, L | 1 |
| Odemis, B | 1 |
| Kilic, M | 1 |
| Altintas, E | 1 |
| Zengin, N | 1 |
| Altiparmak, E | 1 |
| Herrine, SK | 1 |
| Brown, RS | 1 |
| Bernstein, DE | 1 |
| Ondovik, MS | 1 |
| Lentz, E | 1 |
| Te, H | 1 |
| Ricci, GL | 1 |
| Persico, M | 1 |
| Minerva, N | 2 |
| Carretta, V | 2 |
| Bacca, D | 2 |
| Cela, M | 1 |
| Piattelli, M | 1 |
| Annese, M | 2 |
| Maio, G | 1 |
| Conte, D | 1 |
| Guadagnino, V | 1 |
| Pazienza, V | 1 |
| Festi, D | 1 |
| Spirito, F | 1 |
| Younossi, ZM | 3 |
| McCullough, AC | 2 |
| Barnes, DS | 2 |
| Post, A | 1 |
| Ong, JP | 1 |
| O'Shea, R | 1 |
| Martin, LM | 1 |
| Bringman, D | 1 |
| Farmer, D | 1 |
| Levinthal, G | 1 |
| Mullen, KD | 2 |
| Carey, WD | 2 |
| Tavill, AS | 1 |
| Ferguson, R | 1 |
| Gramlich, T | 2 |
| Khattab, E | 1 |
| Chemin, I | 1 |
| Vuillermoz, I | 1 |
| Vieux, C | 1 |
| Mrani, S | 1 |
| Guillaud, O | 1 |
| Trepo, C | 1 |
| El-Zayadi, AR | 2 |
| Attia, M | 2 |
| Badran, HM | 2 |
| El-Tawil, A | 2 |
| Zalata, K | 1 |
| Barakat, E | 1 |
| Selim, O | 2 |
| El-Nakeeb, A | 2 |
| Saied, A | 2 |
| Sethi, A | 1 |
| Lörke, J | 1 |
| Avci, A | 1 |
| Erhardt, A | 1 |
| Heintges, T | 1 |
| Häussinger, D | 1 |
| Lim, JK | 1 |
| Wooten, D | 1 |
| Siegel, R | 1 |
| Cheung, RC | 1 |
| Barakat, EM | 1 |
| Hamdy, H | 1 |
| Laferl, H | 1 |
| Gschwantler, M | 1 |
| Brunner, H | 1 |
| Hubmann, R | 1 |
| Kessler, HH | 1 |
| Klingler, A | 1 |
| Friedrich-Rust, M | 1 |
| Forestier, N | 1 |
| Hoepffner, N | 1 |
| Paul, KA | 1 |
| Nikodem, AB | 1 |
| Grigorian, N | 1 |
| Albrecht, M | 1 |
| Lengauer, T | 1 |
| Manns, MP | 1 |
| Wedemeyer, H | 1 |
| Cornberg, M | 1 |
| Ciancio, A | 1 |
| Giordanino, C | 1 |
| Smedile, A | 1 |
| Manca, A | 2 |
| Marenco, G | 1 |
| Garbagnoli, P | 1 |
| Andreoni, M | 2 |
| Cariti, G | 3 |
| Calleri, G | 2 |
| Sartori, M | 1 |
| Cusumano, S | 2 |
| Grasso, A | 2 |
| Rizzi, R | 1 |
| Gallo, M | 1 |
| Anselmo, M | 1 |
| Percario, G | 1 |
| Ciccone, G | 1 |
| Rizzetto, M | 2 |
| Saracco, G | 1 |
| Castelain, S | 1 |
| Bonte, D | 1 |
| Penin, F | 1 |
| François, C | 1 |
| Capron, D | 1 |
| Dedeurwaerder, S | 1 |
| Zawadzki, P | 1 |
| Morel, V | 1 |
| Wychowski, C | 1 |
| Duverlie, G | 1 |
| Salmerón, J | 1 |
| Diago, M | 1 |
| Andrade, R | 1 |
| Pérez, R | 1 |
| Solá, R | 1 |
| Romero, M | 1 |
| de la Mata, M | 1 |
| Granados, R | 1 |
| Ruiz-Extremera, A | 1 |
| Muñoz de Rueda, P | 1 |
| Taheri, MR | 1 |
| Calanca, LN | 1 |
| Fehr, T | 1 |
| Jochum, W | 1 |
| Fischer-Vetter, J | 1 |
| Müllhaupt, B | 1 |
| Wüthrich, RP | 1 |
| Ambühl, PM | 1 |
| Weigand, K | 1 |
| Encke, J | 1 |
| Gramenzi, A | 1 |
| Andreone, P | 1 |
| Cursaro, C | 1 |
| Boccia, S | 1 |
| Giacomoni, PL | 1 |
| Galli, S | 1 |
| Furlini, G | 1 |
| Biselli, M | 1 |
| Lorenzini, S | 1 |
| Attard, L | 1 |
| Bonvicini, F | 1 |
| Bernardi, M | 1 |
| De Blasi, T | 1 |
| Aguilar Marucco, D | 1 |
| Maiello, A | 1 |
| De Rosa, FG | 1 |
| Di Perri, G | 1 |
| Minutilli, E | 1 |
| Pompili, M | 1 |
| Pelecca, G | 1 |
| Rapaccini, GL | 1 |
| Gasbarrini, G | 1 |
| Castagneto, M | 1 |
| Eisenburg, J | 1 |
| Hermann, R | 1 |
| Ercole, E | 1 |
| Zaffino, C | 1 |
| Sallio Bruno, F | 1 |
| Pera, A | 2 |
| Bonino, F | 1 |
| Martín, J | 1 |
| Navas, S | 1 |
| Fernández, M | 1 |
| Rico, M | 1 |
| Pardo, M | 1 |
| Quiroga, JA | 1 |
| Zahm, F | 1 |
| Carreño, V | 1 |
| Perrillo, RP | 1 |
| Marcellin, P | 1 |
| Foli, M | 2 |
| Di Tomaso, M | 1 |
| Gramantieri, L | 1 |
| Masci, C | 1 |
| Bolondi, L | 2 |
| Hubert, IF | 1 |
| Cadranel, JF | 2 |
| Oberti, F | 1 |
| Calès, P | 1 |
| Schalm, SW | 1 |
| Brouwer, JT | 1 |
| Bekkering, FC | 1 |
| van Rossum, TG | 1 |
| Khalili, M | 1 |
| Denham, C | 1 |
| Perrillo, R | 1 |
| Masi, L | 1 |
| Goff, JS | 1 |
| Reveille, RM | 1 |
| Johnson, J | 1 |
| Naumann, U | 3 |
| Raedle, J | 2 |
| Hartmann, S | 1 |
| Senturk, H | 1 |
| Mert, A | 1 |
| Akdogan, M | 1 |
| Tabak, F | 1 |
| Basaran, G | 1 |
| Turkoglu, S | 1 |
| Ozbay, G | 1 |
| Badur, S | 1 |
| Glaser, D | 1 |
| Carlsson, T | 1 |
| Lindahl, K | 1 |
| Schvarcz, R | 1 |
| Wejstal, R | 1 |
| Uhnoo, I | 1 |
| Shev, S | 1 |
| Reichard, O | 1 |
| Grahovac, B | 1 |
| Bingulac-Popovic, J | 1 |
| Vucelic, B | 1 |
| Hrstic, I | 1 |
| Ostojic, R | 1 |
| Drazic, V | 1 |
| Balija, M | 1 |
| Grgicevic, D | 1 |
| Andant, C | 1 |
| Lamoril, J | 1 |
| Deybach, JC | 1 |
| Jouet, P | 1 |
| Soulé, JC | 1 |
| Zakko, W | 1 |
| Hodnick, S | 1 |
| Brand, E | 1 |
| Easley, K | 1 |
| Boparai, N | 1 |
| Di Martino, V | 1 |
| Boudjema, H | 1 |
| Delacour, T | 1 |
| Cazier, A | 1 |
| Caron, C | 1 |
| Coutarel, P | 1 |
| Dumouchel, P | 1 |
| Wiedenmann, B | 1 |
| Villani, MR | 1 |
| Santoro, R | 1 |
| Giangaspero, A | 1 |
| Bisceglia, M | 1 |
| Ventrella, F | 1 |
| Dell'Erba, G | 1 |
| Brinkmann, S | 1 |
| Gaeta, GB | 1 |
| Stornaiuolo, G | 1 |
| Stanzione, M | 1 |
| Ascione, T | 1 |
| Pasquazzi, C | 1 |
| Taliani, G | 1 |
| Cimino, L | 1 |
| Budillon, G | 1 |
| Piccinino, F | 1 |
| Giusto, R | 1 |
| Brizzolara, R | 1 |
| Campo, N | 1 |
| Sinelli, N | 1 |
| Balestra, V | 1 |
| Laudi, C | 1 |
| Delmastro, B | 1 |
| Biglino, A | 1 |
| Chieppa, F | 1 |
| Bonardi, R | 1 |
| Brunello, F | 1 |
| Della Monica, P | 1 |
| Bassendine, MF | 1 |
| Barry, R | 1 |
| Mills, P | 1 |
| Naoumov, NV | 1 |
| Fox, R | 1 |
| Lowes, J | 1 |
| Hollanders, D | 1 |
| Murray-Lyon, L | 1 |
| Irving, WL | 1 |
| Goldin, RD | 1 |
| Craxi, A | 1 |
| Lo Lacono, O | 1 |
| Yagura, M | 1 |
| Harada, H | 1 |
| Nakamura, H | 1 |
| Koczorek, M | 1 |
| Stamenic, I | 1 |
| Viani, F | 1 |
| Gonvers, JJ | 1 |
| Dufour, JF | 1 |
| Reichen, J | 1 |
| Cathomas, G | 1 |
| Steuerwald, M | 1 |
| Borovicka, J | 1 |
| Sagmeister, M | 1 |
| Pérez-Alvarez, R | 1 |
| Pérez-López, R | 1 |
| Lombraña, JL | 1 |
| Rodríguez, M | 1 |
| Rodrigo, L | 1 |
| Chan, J | 1 |
| O'Riordan, K | 1 |
| Wiley, TE | 1 |
| Idéo, G | 1 |
| Bellobuono, A | 1 |
| Moreno Monteagudo, JA | 2 |
| García Buey, L | 2 |
| Moreno Otero, R | 2 |
| Trapero Marugán, M | 1 |
| Zilly, M | 1 |
| Lingenauber, C | 1 |
| Desch, S | 1 |
| Väth, T | 1 |
| Klinker, H | 1 |
| Langmann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients[NCT00146016] | Phase 3 | 390 participants | Interventional | 2000-02-29 | Completed | ||
| Phase 4 Comparative Study of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4[NCT00502099] | Phase 4 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
33 reviews available for amantadine and Chronic Hepatitis C
| Article | Year |
|---|---|
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon al | 2014 |
Aminoadamantanes for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interf | 2014 |
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Myco | 2014 |
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Human | 2010 |
[Chronic hepatitis C in HIV-HCV coinfected patients].
Topics: Adult; Age Factors; Amantadine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, | 2002 |
[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
Topics: Amantadine; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combina | 2002 |
[Evaluation of response to treatment in chronic hepatitis C].
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzy | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol | 2002 |
Treatment of chronic hepatitis C in nonresponders to previous therapy.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon al | 2003 |
[Combination therapy for chronic viral hepatitis C].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon al | 2003 |
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; D | 2004 |
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-al | 2004 |
Evaluation of amantadine in chronic hepatitis C: a meta-analysis.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Randomized Controlled | 2004 |
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
Topics: Adjuvants, Immunologic; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chroni | 2004 |
[Future antiviral therapy for chronic hepatitis C].
Topics: Adjuvants, Immunologic; Amantadine; Animals; Antiviral Agents; Cysteine Endopeptidases; DNA-Directed | 2004 |
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
Topics: Adjuvants, Immunologic; Alcoholism; Amantadine; Antiviral Agents; Black or African American; Clinica | 2004 |
Treatment of acute and chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; M | 1997 |
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug T | 2005 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatit | 2005 |
Amantadine in treatment of chronic hepatitis C virus infection?
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans | 2005 |
[High dose repeat therapy in previously treated patients with chronic hepatitis C].
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis | 2006 |
Treating viral hepatitis C: efficacy, side effects, and complications.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment O | 2006 |
Treatment of hepatitis C virus infection.
Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon a | 2007 |
[Therapy of chronic hepatitis C: facing a breakthrough?].
Topics: Amantadine; Clinical Trials as Topic; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Inter | 1998 |
[Chronic hepatitis C--therapeutic modalities for interferon failure].
Topics: Amantadine; Antiviral Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Admi | 1998 |
The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
Topics: Amantadine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cholagogues and Choleretics; | 1999 |
New treatment strategies in non-responder patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; | 1999 |
Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck?
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans | 2001 |
Management of interferon therapy nonresponders.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combinatio | 2001 |
New therapies for the treatment of chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon al | 2002 |
[Treatment of chronic hepatitis C in patients not responding to interferon].
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failur | 2000 |
[Antiviral treatment of chronic hepatitis C in interferon nonresponders].
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-al | 2002 |
59 trials available for amantadine and Chronic Hepatitis C
| Article | Year |
|---|---|
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponde
Topics: Adult; Age Factors; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; He | 2008 |
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy | 2008 |
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hep | 2009 |
A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Topics: Adult; Amantadine; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Fem | 2010 |
No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female | 2010 |
Amantadine in non-responder patients with chronic hepatitis C: a randomized prospective study.
Topics: Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug The | 2012 |
A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantadine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatit | 2002 |
High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therap | 2003 |
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis | 2003 |
Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; | 2003 |
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; | 2003 |
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microb | 2003 |
[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)].
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female | 2003 |
Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepa | 2003 |
Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepaciv | 2004 |
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combinati | 2004 |
A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Drug Combinations; Female; Hepatitis C, Chron | 2004 |
Amantadine therapy in renal transplant patients with hepatitis C virus infection.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Aspartate Aminotransferases; Cyclosporine | 2004 |
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
Topics: Adult; Amantadine; Audiometry; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2004 |
[Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha].
Topics: Amantadine; Antiviral Agents; Autoantibodies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug T | 2004 |
Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?
Topics: Adult; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2004 |
Amantadine therapy for chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Child; Double-Blind Me | 2004 |
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Ch | 2004 |
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Aman | 2004 |
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Austria; Dose-Response Relationship, Drug; Drug Combinati | 2004 |
Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).
Topics: Adult; Amantadine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Geno | 2005 |
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hem | 2005 |
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Amantadine; Biopsy, Needle; Chi-Square Distribution; Dose-Response Relation | 2005 |
Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female | 2005 |
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; | 2005 |
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
Topics: Adult; Amantadine; Antiviral Agents; Drug Carriers; Drug Combinations; Drug Costs; Female; Follow-Up | 2005 |
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug T | 2006 |
Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
Topics: Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Hep | 2006 |
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chro | 2006 |
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
Topics: Adult; Aged; Amantadine; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; G | 2007 |
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans | 2007 |
Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
Topics: Adult; Amantadine; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatit | 2007 |
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; | 2007 |
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combinatio | 2007 |
Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Amantadine; Analysis of Variance; Antiviral Agents; Enzyme-Linked Immun | 1998 |
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepati | 1999 |
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Amantadine; Clinical Enzyme Tests; Drug Therapy, Combination; Female; H | 2000 |
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Hepa | 2000 |
Treatment of chronic hepatitis C with amantadine.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic | 2000 |
Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combinatio | 2000 |
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Ch | 2000 |
Amantadine for chronic hepatitis C: pilot study in 14 patients.
Topics: Administration, Oral; Adult; Amantadine; Antiviral Agents; Female; Follow-Up Studies; Hepacivirus; H | 2000 |
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; H | 2001 |
Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon | 2001 |
A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; | 2001 |
Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Double-Blind Method; Drug Therapy, Combinatio | 2001 |
Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow- | 2001 |
Clearance kinetics of hepatitis C virus under different antiviral therapies.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis | 2001 |
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans | 2001 |
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; | 2001 |
Treatment of chronic hepatitis C patients with amantadine.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Amantadine; Antiviral Agents; Cataract; Cognit | 2001 |
Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Amantadine; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Female; Hepatitis C | 2002 |
Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine.
Topics: Adult; Amantadine; Antiviral Agents; Drug Synergism; Female; Hepatitis C, Chronic; Humans; Interfero | 2002 |
36 other studies available for amantadine and Chronic Hepatitis C
| Article | Year |
|---|---|
Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
Topics: Amantadine; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; | 2013 |
Treatment of decompensated cirrhosis secondary to hepatitis C with antiviral therapy.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; | 2013 |
Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo.
Topics: Amantadine; Animals; Antiviral Agents; Callithrix; Cell Line; Disease Models, Animal; Drug Design; G | 2008 |
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chr | 2008 |
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
Topics: Adrenal Cortex Hormones; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis | 2009 |
Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy.
Topics: Adult; alpha 1-Antitrypsin; Amantadine; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; | 2010 |
Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C.
Topics: Adult; Amantadine; Antigens, CD; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; G | 2010 |
Amantadine for treatment of hepatitis C: time to say "enough is enough"?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C, Chron | 2010 |
Chronic hepatitis C treatment in näive patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic | 2010 |
Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Administration Schedule; Hepacivirus | 2003 |
The treatment of viral hepatitis, present and future.
Topics: Amantadine; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C, Chronic; Humans | 2003 |
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, | 2003 |
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans | 2004 |
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Biomarkers; Combined Modality Therapy; Cytokines; Enzyme-Linked | 2004 |
Amantadine therapy for chronic hepatitis C: a dose escalation study.
Topics: Administration, Oral; Adult; Aged; Amantadine; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
Topics: Amantadine; Antiviral Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combi | 2004 |
Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Topics: Adult; Amantadine; Amino Acid Sequence; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female | 2005 |
[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
Topics: Amantadine; Antiviral Agents; Genotype; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatovirus; Hum | 2005 |
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; | 2006 |
Long-term treatment with the combination of amantadine and ribavirin in hepatitis C nonresponders. A case series.
Topics: Amantadine; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; D | 2007 |
Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b.
Topics: Adult; Amantadine; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepacivirus; Hepat | 2008 |
Amantadine-induced livedo reticularis occurring during treatment of chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Livedo Reticularis; Middle Aged; | 2008 |
[Amantadine--a new option in chronic hepatitis C?].
Topics: Adult; Aged; Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Sch | 1998 |
Amantadine in the treatment of patients with chronic hepatitis C.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; | 1998 |
In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.
Topics: 2',5'-Oligoadenylate Synthetase; Amantadine; Antiviral Agents; Cells, Cultured; Drug Therapy, Combin | 1999 |
Combination therapy for chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-al | 1999 |
Treatment of chronic hepatitis C with amantadine.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Long-T | 1999 |
Amantadine monotherapy of chronic hepatitis C patients infected with genotype lb.
Topics: Adolescent; Adult; Amantadine; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic | 2000 |
Re: Khalili et al.--chronic Hepatitis C treatment in interferon nonresponders.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; | 2000 |
Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hep | 2001 |
Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Topics: Adult; Aged; Amantadine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2001 |
Efficacy of amantadine hydrochloride in patients with chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans | 2001 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |
Amantadine's viral kinetics in chronic hepatitis C infection.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Human | 2002 |
Amantadine: a different approach.
Topics: Amantadine; Antiviral Agents; Hepatitis C, Chronic; Humans | 2002 |
Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis C, Chronic; Hum | 2002 |